NCT05899439

Brief Summary

To elucidate the mechanisms by which type 1 diabetes-associated genes; IFIH1, TYK2, IKZF4, as well as total genetic risk, impart functional immunoregulatory abnormalities that result in expansion of self-reactive adaptive immune cells, defective regulatory/effector mechanisms in T cells, inflammatory antigen presenting cells, and abnormal immune function in T cells and B cells.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,800

participants targeted

Target at P75+ for all trials

Timeline
714mo left

Started Jan 2005

Longer than P75 for all trials

Geographic Reach
1 country

3 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress27%
Jan 2005Jan 2085

Study Start

First participant enrolled

January 1, 2005

Completed
18.4 years until next milestone

First Submitted

Initial submission to the registry

May 22, 2023

Completed
21 days until next milestone

First Posted

Study publicly available on registry

June 12, 2023

Completed
61.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2085

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2085

Last Updated

April 9, 2026

Status Verified

April 1, 2026

Enrollment Period

80.1 years

First QC Date

May 22, 2023

Last Update Submit

April 3, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • the number of participants who become at risk for development of type 1 diabetes

    the number of participants who become at risk for development of type 1 diabetes

    through study completion, up to 25 years

  • Genetic risk of type 1 diabetes

    the number of people in different genetic risk groups who develop type 1 diabetes

    through study completion, up to 25 years

Study Arms (2)

Subjects with diabetes age 0 to 100 years

People who have not been diagnosed with type 1 diabetes

Other: blood draw

Subjects with type 1 diabetes age 0 to 100 years

People who have been diagnosed with type 1 diabetes

Other: blood draw

Interventions

a peripheral blood draw

Subjects with diabetes age 0 to 100 yearsSubjects with type 1 diabetes age 0 to 100 years

Eligibility Criteria

Age0 Years - 100 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Individuals age 0 to 100 with or without a diagnosis of type 1 diabetes and able/willing to have a blood draw

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Kieran McGrail

Gainesville, Florida, 32610, United States

RECRUITING

The Ohio State University

Columbus, Ohio, 43210, United States

RECRUITING

Baylor College of Medicine, Center for Research Advancement - Texas Children's Hospital

Houston, Texas, 77030, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Sample collections, mainly peripheral blood but also discarded clinical samples, will occur at clinics, research space, and special event spaces on the University of Florida campus and remotely via lab collection. Genetic analysis will be performed related to developing a genetic model for predicting type 1 diabetes in the general population.

MeSH Terms

Conditions

Diabetes Mellitus, Type 1

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Central Study Contacts

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 22, 2023

First Posted

June 12, 2023

Study Start

January 1, 2005

Primary Completion (Estimated)

January 1, 2085

Study Completion (Estimated)

January 1, 2085

Last Updated

April 9, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will share

the data generated from the proposed studies will be presented at national or international conferences and published in a timely fashion. Investigators associated with this P01 have a record of publishing in pre-print servers and favoring open-access journals, when appropriate. The investigator will implement field standard, open-source tools including those developed by investigators on this proposal for data processing. Importantly, raw data, processed data, and metadata will be stored locally as well as deposited on public databases as detailed further below. All final peer-reviewed manuscripts that arise from this proposal will be submitted to the digital archive PubMed Central. Evidence of this is provided in the attached biosketches.

Locations